Status:
COMPLETED
APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Lead Sponsor:
Heartcenter, University Medical Center St. Radboud
Collaborating Sponsors:
Netherlands Heart Foundation
The Interuniversity Cardiology Institute of the Netherlands
Conditions:
Myocardial Infarction
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Reocclusion of the infarct artery is observed in about 30% of patients within three months after successful thrombolysis for acute myocardial infarction (MI). Reocclusion is associated with an increas...
Detailed Description
Randomized controlled study of elective percutaneous coronary intervention (PCI) of an open culprit lesion after fibrinolysis for ST-elevation myocardial infarction (STEMI)
Eligibility Criteria
Inclusion
- TIMI-3 in infarct-related artery with a stentable lesion with 72 hours of thrombolysis for ST-elevation myocardial infarction
Exclusion
- Use of oral anticoagulants.
- Known intolerance to aspirin or clopidogrel.
- Bypass graft as infarct-related artery.
- Previously dilated infarct related artery.
- Significant left main stenosis.
- Unidentifiable culprit stenosis.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00138034
Start Date
January 1 2005
End Date
February 1 2010
Last Update
April 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Center
Nijmegen, Gelderland, Netherlands, 6500 HB